Thomas Watkins

Thomas Watkins (board member) discloses dealings in 3 companies, chiefly Horizon Therapeutics Public Ltd Co, Human Genome Sciences Inc and Vanda Pharmaceuticals Inc. Over a trading history stretching from 5 September 2006 to 6 October 2023, the count stands at 50 filings.

The open-market side counts 14 purchases for €2.0M alongside 4 sales for €694k. Taken together, the purchases exceed the sales by €1.3M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 7 share grants and 16 option exercises.

In size, the median ticket on the buying side is €32k.

On 6 October 2023 came the latest disclosure, a transaction for €6.2M in Horizon Therapeutics Public Ltd Co. The most recent open-market purchase was published on 21 August 2015, 4,082 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.